Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 212-219

  Carlson, Brett L ^a   Grogan, Patrick T ^a   Mladek, Ann C ^a   Schroeder, Mark A ^a   Kitange, Gaspar J ^a   Decker, Paul A ^a   Giannini, Caterina ^a   Wu, Wenting ^a   Ballman, Karla A ^a   James, C David ^b   Sarkaria, Jann N ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioblastoma; MGMT; Radiation; Temozolomide; Xenografts

Indexed keywords

ANTI-TUMOR ACTIVITIES; COMBINED THERAPY; DNA METHYLTRANSFERASES; GLIOBLASTOMA; GLIOBLASTOMA MULTIFORME; IN-VIVO; MEDIAN SURVIVAL; MGMT; RADIATION THERAPY; RELATIVE CONTRIBUTION; SEQUENTIAL TREATMENTS; SURVIVAL RATIO; TEMOZOLOMIDE; TREATMENT RESPONSE; XENOGRAFTS;

BIOLOGICAL MATERIALS; DNA; ENZYMES; GENES; NUCLEIC ACIDS; REGRESSION ANALYSIS; TUMORS;

ONCOLOGY;

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLACEBO; PROTEIN P53; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; METHYLATION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; GENES, ERBB-1; GENES, P53; GLIOBLASTOMA; HUMANS; METHYLATION; MICE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PTEN PHOSPHOHYDROLASE; RADIATION-SENSITIZING AGENTS; RANDOM ALLOCATION; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68649090475     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.026     Document Type: Article

References (32)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Hegi M.E., Diserens A.-C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
3. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10 (2004) 4933-4938
4. Lawrence T.S., Blackstock A.W., and McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13 (2003) 13-21
5. McGinn C.J., and Lawrence T.S. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 11 (2001) 270-280
6. Byfield J.E. 5-Fluorouracil radiation sensitization--A brief review. Invest New Drugs 7 (1989) 111-116
7. Wedge S.R., Porteous J.K., Glaser M.G., et al. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8 (1997) 92-97
8. van Rijn J., Heimans J.J., van den Berg J., et al. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47 (2000) 779-784
9. Chakravarti A., Erkkinen M.G., Nestler U., et al. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res 12 (2006) 4738-4746
10. Combs S.E., Schulz-Ertner D., Roth W., et al. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 68 (2007) 873-882
11. van Nifterik K.A., van den Berg J., Stalpers L.J.A., et al. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 69 (2007) 1246-1253
12. Kitange G.J., Carlson B.L., Schroeder M.A., et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncol 92 (2009) 23-31
13. Dinca E.B., Lu K.V., Sarkaria J.N., et al. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 68 (2008) 10034-10039
14. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 (2000) 588-593
15. Brada M., Hoang-Xuan K., Rampling R., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12 (2001) 259-266
16. Sarkaria J.N., Carlson B.L., Schroeder M.A., et al. Use of an Orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 12 (2006) 2264-2271
17. Sarkaria J.N., Yang L., Grogan P.T., et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 6 (2007) 1167-1174
18. Yang L., Clarke M.J., Carlson B.L., et al. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 14 (2008) 3993-4001
19. Esteller M., Hamilton S.R., Burger P.C., et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59 (1999) 793-797
20. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000) 1350-1354
21. James C.D., Galanis E., Frederick L., et al. Tumor suppressor gene alterations in malignant gliomas: Histopathological associations and prognostic evaluation. Int J Oncol 15 (1999) 547-553
22. Giannini C., Hebrink D., Scheithauer B.W., et al. Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics 3 (2001) 159-162
23. Smith J.S., Tachibana I., Passe S.M., et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93 (2001) 1246-1256
24. Liu W., James C.D., Frederick L., et al. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57 (1997) 5254-5257
25. Hegi M.E., Diserens A.-C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10 (2004) 1871-1874
26. Stevens M.F., Hickman J.A., Langdon S.P., et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47 (1987) 5846-5852
27. Baker S.D., Wirth M., Statkevich P., et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5 (1999) 309-317
28. Reid J.M., Stevens D.C., Rubin J., et al. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3 (1997) 2393-2398
29. Giannini C., Sarkaria J., Saito A., et al. Patient Tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of GBM. Neuro-oncol 7 (2005) 164-176
30. Pandita A., Aldape K.D., Zadeh G., et al. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39 (2004) 29-36
31. Jackson P.E., Cooper D.P., Meyer T.A., et al. Formation and persistence of O(6)-methylguanine in the mouse colon following treatment with 1,2-dimethylhydrazine as measured by an O(6)-alkylguanine-DNA alkyltransferase inactivation assay. Toxicol Lett 115 (2000) 205-212
32. O'Connor P.J., Manning F.C., Gordon A.T., et al. DNA repair: kinetics and thresholds. Toxicol Pathol 28 (2000) 375-381